Chipmaker Astera Labs, Inc. late Tuesday handily beat analyst estimates for the second quarter and guided higher for the current period. Astera Labs’ stock rose 32% on Wednesday.

The San Jose, Calif.-based company earned an adjusted 44 cents a share on sales of $191.9 million in the June quarter. Analysts polled by FactSet had expected earnings of 32 cents a share on sales of $172.5 million. In the year-earlier period, Astera Labs earned an adjusted 13 cents a share on sales of $76.9 million. That translates to year-over-year growth of 238% in earnings and 150% in sales.

Centrus reported second quarter earnings that significantly exceeded analyst expectations, driving shares up 23% as investors cheered the nuclear fuel company’s strong performance.

The American nuclear fuel supplier posted adjusted earnings of $1.59 per diluted share for the second quarter of 2025, handily beating the analyst consensus of $0.84 by 89%. Revenue came in at $154.5 million, surpassing the $130.18 million analysts had expected and despite being down 18% from $189 million in the same quarter last year.

Novavax rose 17% on Wednesday after the Maryland-based biotech reported better-than-expected Q2 financials and raised its 2025 revenue outlook, citing, among other things, collaborations related to its COVID shot, Nuvaxovid.

The company reported $239.2M in revenue for the quarter, with a ~42% YoY decline while exceeding the consensus by $74.2M, driven by a $175M milestone payment received from its partner Sanofi following the recent FDA approval for Nuvaxovid.

Arista Networks rose about 16% on Wednesday after the company’s forecast third-quarter revenue above Wall Street expectations, signaling resilient demand for its networking equipment amid growing footprint of data centers.